
Richard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.

Richard D. Carvajal, MD, discusses what he sees as the leading factors in making outcomes worse for patients with mucosal melanoma and how the disease differs from treatment for patients with cutaneous melanoma.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses options for treating melanoma after the use of targeted therapies and immunotherapy.

Published: April 17th 2017 | Updated: